Mainz Biomed Bv Stock Alpha and Beta Analysis

MYNZ Stock  USD 7.32  0.40  5.78%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Mainz Biomed BV. It also helps investors analyze the systematic and unsystematic risks associated with investing in Mainz Biomed over a specified time horizon. Remember, high Mainz Biomed's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Mainz Biomed's market risk premium analysis include:
Beta
(29.82)
Alpha
54.41
Risk
125.35
Sharpe Ratio
0.12
Expected Return
15.29
Please note that although Mainz Biomed alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, Mainz Biomed did 54.41  better than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of Mainz Biomed BV stock's relative risk over its benchmark. Mainz Biomed BV has a beta of 29.82  . As returns on the market increase, returns on owning Mainz Biomed are expected to decrease by larger amounts. On the other hand, during market turmoil, Mainz Biomed is expected to outperform it. At this time, Mainz Biomed's Book Value Per Share is fairly stable compared to the past year. Price Book Value Ratio is likely to rise to 6.09 in 2024, despite the fact that Tangible Book Value Per Share is likely to grow to (0.01).

Enterprise Value

18.23 Million

Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out Mainz Biomed Backtesting, Mainz Biomed Valuation, Mainz Biomed Correlation, Mainz Biomed Hype Analysis, Mainz Biomed Volatility, Mainz Biomed History and analyze Mainz Biomed Performance.

Mainz Biomed Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Mainz Biomed market risk premium is the additional return an investor will receive from holding Mainz Biomed long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Mainz Biomed. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Mainz Biomed's performance over market.
α54.41   β-29.82

Mainz Biomed expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Mainz Biomed's Buy-and-hold return. Our buy-and-hold chart shows how Mainz Biomed performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

Mainz Biomed Market Price Analysis

Market price analysis indicators help investors to evaluate how Mainz Biomed stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Mainz Biomed shares will generate the highest return on investment. By understating and applying Mainz Biomed stock market price indicators, traders can identify Mainz Biomed position entry and exit signals to maximize returns.

Mainz Biomed Return and Market Media

The median price of Mainz Biomed for the period between Fri, Sep 6, 2024 and Thu, Dec 5, 2024 is 0.26 with a coefficient of variation of 249.33. The daily time series for the period is distributed with a sample standard deviation of 1.19, arithmetic mean of 0.48, and mean deviation of 0.4. The Stock received a lot of media exposure during the period.
 Price Growth (%)  
       Timeline  
1
Pfizer Advances On Its Cancer Journey
09/20/2024
2
Mainz Biomed Publishes CEO Statement CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
10/01/2024
3
Former Senior Advisor To Obama Joins Forces WIth Innovative Biotech To Catch Cancer Early
10/04/2024
4
Critical Analysis TetraLogic Pharmaceuticals versus Mainz Biomed
10/11/2024
5
What Mainz Biomed Has Been Up To Recently And Why Frankie Muniz Is A Backer
11/11/2024
6
Mainz Biomed Considers Reverse Stock Split for Nasdaq Compliance - TipRanks
11/15/2024
7
Mainz Biomed Downgraded by HC Wainwright to Neutral
11/25/2024
8
Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific
12/03/2024

About Mainz Biomed Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Mainz or other stocks. Alpha measures the amount that position in Mainz Biomed BV has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
 2021 2022 2023 (projected)
Graham Number5.766.472.7
Receivables Turnover32.512.042.53

Mainz Biomed Upcoming Company Events

As portrayed in its financial statements, the presentation of Mainz Biomed's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Mainz Biomed's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Mainz Biomed's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Mainz Biomed. Please utilize our Beneish M Score to check the likelihood of Mainz Biomed's management manipulating its earnings.
8th of April 2024
Upcoming Quarterly Report
View
21st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
8th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Build Portfolio with Mainz Biomed

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Additional Tools for Mainz Stock Analysis

When running Mainz Biomed's price analysis, check to measure Mainz Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mainz Biomed is operating at the current time. Most of Mainz Biomed's value examination focuses on studying past and present price action to predict the probability of Mainz Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mainz Biomed's price. Additionally, you may evaluate how the addition of Mainz Biomed to your portfolios can decrease your overall portfolio volatility.